Telix Pharmaceuticals Ltd (ASX:TLX) shares jumped as much as 9% in early Tuesday trade after securing a “resubmission pathway” with the US Food and Drug Administration (FDA) for its brain cancer imaging drug, Pixclara.
The FDA had rejected Telix’s original application in April, sending the stock tumbling from above $29. On Tuesday, Telix was last up 8.8% at $14.80.